2023-503388-40-00CompletedPhase 1
A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC).
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Apr 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 15 Sept 2023
- Start date
- 24 Aug 2021
- Lead sponsor
- Seagen Inc.
- Diseases
- Bladder cancer
- EU CT number
- 2023-503388-40-00
- EudraCT number
- 2021-001287-22
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 10 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fraunhofer Institute For Translational Medicine And Pharmacology ITMP | Goettingen | Germany | Completed |
| Universitaetsmedizin Goettingen | Goettingen | Germany | Completed |
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Germany | Completed |
| Hospital Clinic de Barcelona | Barcelona | Spain | Completed |
| Fundació Puigvert | Barcelona | Spain | Completed |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Completed |
| Hospices Civils De Lyon | Lyon Cedex 03 | France | Completed |
| Assistance Publique Hopitaux de Paris | Paris | France | Completed |
| Centre Hospitalier Universitaire de Rennes | Rennes | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.